BACKGROUND: The identification of individuals at the highest risk of human immunodeficiency virus (HIV) infection is critical for targeting prevention strategies. We evaluated self-perceived risk of HIV infection and rates of subsequent HIV seroconversion among a prospective cohort study of injection drug users (IDUs). METHODS: We performed an analysis of the time to HIV infection among 994 baseline HIV negative IDUs enrolled in the Vancouver injection drug users study (VIDUS). IDUs were stratified based on their baseline self-perceived risk of HIV seroconversion (higher than others vs same or lower). Kaplan-Meier methods were used to estimate cumulative HIV incidence rates and Cox regression was used to determine adjusted relative hazards for HIV seroconversion. RESULTS: At the end of 24 months after enrolment into the cohort, the cumulative HIV incidence rate was significantly elevated among the 5.9% of the sample who perceived their risk for HIV infection to be higher at baseline (26.6% vs 7.8% log-rank P < 0.001). In a Cox model that adjusted for all variables that were associated with the time to HIV infection in univariate analyses, a higher baseline self-perceived risk of acquiring HIV infection (relative hazard RH: 2.48 [95% Confidence interval (CI): 1.51, 4.10]; P = 0.004) remained independently associated with time to HIV seroconversion. CONCLUSIONS: IDUs' perception of their risk for HIV seroconversion upon enrolment into a prospective cohort study was strongly and independently associated with the subsequent rate of HIV seroconversion. Since this risk marker remained independently associated with HIV seroconversion, even after adjustment for time-updated risk behaviours, our findings have major implications that may aid outreach workers in their efforts to identify IDUs who should be targeted with prevention efforts.
BACKGROUND: The identification of individuals at the highest risk of human immunodeficiency virus (HIV) infection is critical for targeting prevention strategies. We evaluated self-perceived risk of HIV infection and rates of subsequent HIV seroconversion among a prospective cohort study of injection drug users (IDUs). METHODS: We performed an analysis of the time to HIV infection among 994 baseline HIV negative IDUs enrolled in the Vancouver injection drug users study (VIDUS). IDUs were stratified based on their baseline self-perceived risk of HIV seroconversion (higher than others vs same or lower). Kaplan-Meier methods were used to estimate cumulative HIV incidence rates and Cox regression was used to determine adjusted relative hazards for HIV seroconversion. RESULTS: At the end of 24 months after enrolment into the cohort, the cumulative HIV incidence rate was significantly elevated among the 5.9% of the sample who perceived their risk for HIV infection to be higher at baseline (26.6% vs 7.8% log-rank P < 0.001). In a Cox model that adjusted for all variables that were associated with the time to HIV infection in univariate analyses, a higher baseline self-perceived risk of acquiring HIV infection (relative hazard RH: 2.48 [95% Confidence interval (CI): 1.51, 4.10]; P = 0.004) remained independently associated with time to HIV seroconversion. CONCLUSIONS: IDUs' perception of their risk for HIV seroconversion upon enrolment into a prospective cohort study was strongly and independently associated with the subsequent rate of HIV seroconversion. Since this risk marker remained independently associated with HIV seroconversion, even after adjustment for time-updated risk behaviours, our findings have major implications that may aid outreach workers in their efforts to identify IDUs who should be targeted with prevention efforts.
Authors: Mark A Brockman; Denis R Chopera; Alex Olvera; Chanson J Brumme; Jennifer Sela; Tristan J Markle; Eric Martin; Jonathan M Carlson; Anh Q Le; Rachel McGovern; Peter K Cheung; Anthony D Kelleher; Heiko Jessen; Martin Markowitz; Eric Rosenberg; Nicole Frahm; Jorge Sanchez; Simon Mallal; Mina John; P Richard Harrigan; David Heckerman; Christian Brander; Bruce D Walker; Zabrina L Brumme Journal: J Virol Date: 2012-04-11 Impact factor: 5.103
Authors: Karla D Wagner; Stephen E Lankenau; Lawrence A Palinkas; Jean L Richardson; Chih-Ping Chou; Jennifer B Unger Journal: Addict Behav Date: 2011-03-25 Impact factor: 3.913
Authors: Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman Journal: Int J Epidemiol Date: 2017-04-01 Impact factor: 7.196
Authors: L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev Journal: Am J Transplant Date: 2011-03-02 Impact factor: 8.086